The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …

Osteoporosis care has evolved markedly over the last 50 years, such that there are now an
established clinical definition, validated methods of fracture risk assessment and a range of …

Osteoporosis, a metabolic bone disease characterized by low bone mineral density and
deterioration of bone microarchitecture, has led to a high risk of fatal osteoporotic fractures …

Osteoporosis (OP) is a chronic bone disease characterized by aberrant microstructure and
macrostructure of bone, leading to reduced bone mass and increased risk of fragile …

Osteoporosis, characterized by low bone mass and a disruption of bone microarchitecture, is
traditionally treated using drugs or lifestyle modifications. Recently, several preclinical and …

Osteoporosis is a systemic bone disease characterized by low bone mass,
microarchitectural deterioration, increased bone fragility, and fracture susceptibility. It …

Despite substantial advances in delineation of the epidemiology, pathophysiology, risk
assessment and treatment of osteoporosis over the last three decades, a substantial …

Osteoarthritis (OA) is a highly prevalent condition characterized by degradation of the joints.
OA and cardiovascular disease (CVD) are leading contributors to disease burden …

Background Osteoporosis and cardiovascular disease are common diseases encountered
globally, especially with advancing age. Osteoporosis occurs when there is a loss of bone …

As a key regulator of bone homeostasis, sclerostin has garnered a lot of interest over the last
two decades. Although sclerostin is primarily expressed by osteocytes and is well known for …